SeaStar Medical Holding Corporation (ICU)
| Previous close | 5.17 |
| Open | 5.04 |
| Bid | 4.93 x 100 |
| Ask | 5.12 x 100 |
| Day's range | 4.91 - 5.31 |
| 52-week range | 3.25 - 42.92 |
| Volume | |
| Avg. volume | 304,641 |
| Market cap | 21.188M |
| Beta (5Y monthly) | -1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -18.55 |
| Earnings date | 12 Nov 2024 - 18 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
GlobeNewswireSeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference
DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 9:00 a.m. Eastern time. A webcast of the fireside chat will be available on the Events and Presentations
- GlobeNewswire
SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt
DENVER, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports that it has now retired all long-term debt, which will be reflected on its balance sheet for the quarter ending September 30, 2024. “At the end of 2023, we reported more than $9 million in convertible notes and long-term interest bearing de
- GlobeNewswire
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update
DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2024 and provides a business update. “Our recent commercial, clinical and corporate achievements have significantly strengthened our company and support an acti
